)
)
)
Rakuten Medical
Rakuten Medical is a clinical and commercial-stage biotech advancing its Alluminox™ photoimmunotherapy platform, which combines a drug and device to treat cancers. Its lead asset, ASP-1929, an EGFR-targeted antibody-dye conjugate, is in a global Phase 3 trial with anti-PD-1 therapy and has been approved in Japan since 2021 for unresectable or recurrent head and neck cancer, with 800+ commercial treatments completed. In December 2024, the company enrolled the first patient in its global Phase 3 1L study, following strong ASCO 2024 data (24-month OS 52.4%, CR 23.5%, with a well-tolerated safety profile). Real-world post-marketing data further confirm efficacy and safety. Rakuten Medical is seeking partners to license and co-develop its technology globally.
What is your next catalyst (value inflection) update?
Interim analysis from ongoing global phase 3 trial for ASP1929 + anti-PD1 in 1st line, recurrent head and neck cancer
Year Founded
2010
Lead Product in Development
ASP-1929
Development Phase of Lead Product
Phase III
Number of Unlicensed Products Looking for Licensing
3
CEO/Top Company Official
Mickey Mikitani, CEO
Minami Maeda, President
Abhijit Bhatia, COO
When you expect your next catalyst update?
March 2026
){kind=logo}
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
